Kimberly Manhard

Insider profile

Currently holds positions in Heron Therapeutics Inc and Ardea Biosciences Inc

Performance

Overall performance
3.7
Performance over holding periods
4.2
30 days 90 days 120 days
Average return 16% 8.2% 15.1%
Success rate 100% 68% 82%
Transactions
6 17% Buy
34 71% Buy
47 69% Buy
Ranking by holding-period performance
Performance for realised trades
4.4
Average return 698%
Success rate 73%
Average holding period 220
Transactions 28
Ranking by realised performance

Positions

Position Company Period
Executive Vice President - Drug Development, Director Heron Therapeutics Inc Oct. 1, 2019 -
Senior Vice President - Regulatory Affairs and Development Operations Ardea Biosciences Inc Dec. 21, 2006 -
Executive Vice President - Drug Development Heron Therapeutics Inc Jan. 27, 2016 - Oct. 1, 2019
Independent Director Heron Therapeutics Inc Jan. 10, 2014 - Jan. 27, 2016
Kimberly Manhard's trades of Inhibrx Biosciences Inc's stock


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Transaction date
Proposed sale
Price
251.12
Quantity 1,538
Value US$4,909,912
Transaction date
Purchase
Price
13.98
Quantity 10,000 New position
Value US$139,800
Transaction date
Planned sale
Price
4.76
Quantity 1,504 -12.2%
Value US$7,154
Transaction date
Planned sale
Price
20.00
Quantity 10,000 -100.0%
Value US$200,000
Transaction date
Planned sale
Price
13.97
Quantity 1,158 -100.0%
Value US$16,176
Transaction date
Planned sale
Price
18.86
Quantity 1,109 -100.0%
Value US$20,918
Notification date Transaction date Company B/S Transaction type Nb. shares
Price
Value 		Number of shares Price Value Details
2026-09-15 2026-09-15
S Sale
16,668 -34.7%
466.32
US$4,360,719 		16,668 -34.7% 466.32 US$4,360,719
2026-09-15 2026-09-15
PrS Proposed sale
1,538
251.12
US$4,909,912 		1,538 251.12 US$4,909,912
2026-09-15 2026-09-14
S Sale
71,063 -39.6%
281.40
US$2,493,819 		71,063 -39.6% 281.40 US$2,493,819
2026-09-14 2026-09-14
PrS Proposed sale
500
110.26
US$55,130 		500 110.26 US$55,130
2026-09-15 2026-09-11
S Sale
500 -5.6%
111.78
US$55,888 		500 -5.6% 111.78 US$55,888
2026-09-11 2026-09-11
PrS Proposed sale
500
111.78
US$55,888 		500 111.78 US$55,888
2026-09-10 2026-09-09
S Sale
500 -5.3%
115.80
US$57,898 		500 -5.3% 115.80 US$57,898
2026-09-09 2026-09-09
PrS Proposed sale
500
115.80
US$57,898 		500 115.80 US$57,898
2026-09-10 2026-09-08
S Sale
500 -5.0%
115.14
US$57,570 		500 -5.0% 115.14 US$57,570
2026-09-08 2026-09-08
PrS Proposed sale
500
115.14
US$57,570 		500 115.14 US$57,570
2024-08-30 2024-08-28
B Purchase
10,000 New position
13.98
US$139,800 		10,000 New position 13.98 US$139,800
2022-05-04 2022-05-03
PlS Planned sale
1,504 -12.2%
4.76
US$7,154 		1,504 -12.2% 4.76 US$7,154
2020-12-23 2020-12-22
PlS Planned sale
10,000 -100.0%
20.00
US$200,000 		10,000 -100.0% 20.00 US$200,000
2020-05-01 2020-05-01
PlS Planned sale
1,158 -100.0%
13.97
US$16,176 		1,158 -100.0% 13.97 US$16,176
2019-05-02 2019-05-01
PlS Planned sale
1,109 -100.0%
18.86
US$20,918 		1,109 -100.0% 18.86 US$20,918